Policy & Regulation

Syngenta’s role in seeds and pesticides makes it vulnerable as U.S.-China farm trade tensions rise.

India’s planned seed and pesticide laws could reshape one of the world’s most important farm-input markets.

Fertilizer access is becoming a G20-level food-security issue as supply disruptions threaten global planting plans.

FDA’s latest color petition shows that the natural-color shift now includes tighter rules on extraction solvents.

India’s tariff cuts could trim agrochemical input costs by up to 9% and improve manufacturing economics.

FSANZ’s acceptance of COR121 marks another step toward broader food-chain clearance for a new insect-resistant corn event.

EPA approval gives Thymoflex a timely opening as U.S. beekeepers look for new tools against Varroa mites.

The FDA’s decision to delay the effective date of two February 2026 final orders involving natural color additives: one approving beetroot red for use in human foods, and another expanding the approved uses of spirulina extract.

After semaglutide patent expiry in India, 40+ drugmakers and 50+ brands rushed in, with monthly treatment prices falling to about US$14, pushing GLP-1 into fully open competition in a large market for the first time.

Brazil expanded chemical tax relief while India’s crop protection industry warned that input costs could rise 25%, showing the Middle East conflict is spreading from oil prices into industrial policy and agricultural security.

EFSA’s latest review keeps clodinafop under pressure by highlighting missing data and key risk concerns.

The FDA added another noteworthy nutrition-related development on March 16, when it posted the agenda and memo for a March 27 public meeting titled “Exploring the Scope of Dietary Supplement Ingredients.”

A quieter but potentially important nutrition story emerged in mid-March when the FDA published a memorandum of understanding with the National Institutes of Health to coordinate the NIH-FDA Nutrition Regulatory Science Program.

The agency said the assessment evaluated how pathogens such as Salmonella, STEC O157:H7, and STEC non-O157 can survive, move through the farm environment, and ultimately reach consumers through contaminated produce.

WACKER posted a €805 million net loss in 2025, while its PACE savings plan is now central to any recovery in 2026.

Key 2026 pharmaceutical regulatory updates across UAE, Saudi Arabia, GCC, Egypt and global agencies, with practical compliance insights for pharma companies.

• UAE
• MENA region
• Drugs
• Regulation
• pharmaceutical policy

Over the past 72 hours, the security situation in key Middle Eastern maritime corridors — the Strait of Hormuz and the Red Sea — has deteriorated again.

FDA loosens “no artificial colors” claims while green-lighting new natural dyes—sparking a fierce debate over what “clean” really means.

FDA reopens BHA safety review, signaling a global shift toward tighter oversight of legacy food additives.